

THE JOURNAL OF  
**CLINICAL PSYCHIATRY**

THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY

## **Supplementary Material**

**Article Title:** Persistence With and Adherence to Paliperidone Palmitate Once-Monthly Injection for Schizophrenia Treatment in China and Japan

**Author(s):** Huaning Wang, MD; Yongjing Zhang, PhD; Jin Liu, MS, Rui Chi, MD; Tao Wu, MS; Ting Zhang, PhD; Lili Zhang, PhD; Kun Jiang, MD; Hong Qiu, PhD; Wentian Dong, MD; and Tianmei Si, MD

**DOI Number:** <https://doi.org/10.4088/JCP.20m13850>


### **List of Supplementary Material for the article**

1. **Figure 1** Cohort selection
2. **Table 1** PP1M utilization by database and AP medications
3. **Table 2** Sensitivity analyses
4. **Figure 2** Sensitivity analyses: Drug persistence, Kaplan-Meier curves
5. **Table 3** Sensitivity analysis, Cox proportional hazard models for persistence
6. **Table 4** Sensitivity analysis, Logistic regression models for good adherence

### **Disclaimer**

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary Figure 1. Cohort Selection



**Supplementary Table 1.** PP1M utilization by database and AP medications

Drug Utilization	JMDC (2014-2017)		PKU (2012-2017)		XJH (2012-2017)	
	PP1M	Oral SGA	PP1M	Oral SGA	PP1M	Oral SGA
<b>Number of prescriptions</b>						
n	249	40 058	428	6 450	189	3 884
Mean (SD)	8.59 (4.75)	12.50 (17.66)	6.76 (4.43)	7.48 (4.60)	4.78 (3.64)	5.17 (3.96)
median	9	9	6	7	4	4
min-max	1-15	1 - 722	1-19	1-51	1-14	1-32
<b>Gap between prescriptions (days)</b>						
n	229	34 749	368	5 754	147	3 071
Mean (SD)	28.51 (7.54)	28.67 (26.13)	42.65 (42.86)	45.12 (37.14)	38.86 (34.77)	43.96 (41.90)
median	28.00	25.29	31.05	35.32	31.22	33.33
min-max	7.00–65.50	1.00– 364.00	2.00-360.00	1.00-364.00	3.00-215.00	1.00-364.00
<b>Dose (mg)</b>						
n	249	-	424	-	189	-
Mean (SD)	103.27 (32.90)	-	110.78 (24.07)	-	115.11 (16.39)	-
Median	100	-	104.55	-	110	-
min-max	25-150	-	75-150	-	95-150	-
<b>First dose (mg)</b>						
n	249	-	424	-	189	-
Mean (SD)	108.13 (37.92)	-	120.87 (31.19)	-	131.48 (24.21)	-
Median	100	-	150	-	150	-
min-max	25-150	-	75-150	-	100-150	-
<b>Last dose (mg)</b>						
n	249	-	424	-	189	-
Mean (SD)	101.41 (36.45)	-	108.49 (28.74)	-	110.32 (20.77)	-
Median	100	-	100	-	100	-
min-max	25-150	-	75-200	-	75-150	-
<b>Number of dose changes</b>						
n	116	-	365	-	147	-
Mean (SD)	1.66 (0.90)	-	1.63 (1.06)	-	1.11 (1.03)	-
median	1	-	1	-	1	-
min-max	0-5	-	0-10	-	0-5	-


SD, standard deviation; n, number of patients with available data; PP1M, Paliperidone palmitate administered once a month; AP, antipsychotic; JMDC, Japan Medical Data Center; PKU, Peking University No.6 Hospital; XJH, Xijing hospital; SGA, second-generation antipsychotic

**Supplementary Table 2.** Sensitivity analyses

Sensitivity analysis	JMDC(2014-2017)		PKU(2012-2017)		XJH(2012-2017)	
	PP1M	Oral SGA	PP1M	Oral SGA	PP1M	Oral_SGA
<b>60-day treatment gap</b>						
<b>Drug persistence within 1 year (days)</b>						
n	249	40 058	428	6 450	189	3 884
Mean (SD)	246.14 (136.30)	215.52 (144.95)	157.94 (129.74)	149.73 (133.09)	106.15 (102.77)	84.98 (88.59)
median	364	238	113	99	65	51
min-max	28-365	1-365	28-365	1-365	28-365	1-365
Good persistence (=365 days)n(%)	120 (48.19)	14610 (36.47)	81 (18.93)	980 (15.19)	13 (6.88)	106 (2.73)
Good persistence ( $\geq$ 183 days) n (%)	156 (62.65)	22476 (56.10)	149 (34.81)	2204 (34.17)	31 (16.40)	508 (13.08)
<b>Index mono-treatment cohort</b>						
<b>Drug persistence within 1 year (days)</b>						
n	94	31549	316	5 632	146	3 586
Mean (SD)	248.90 (135.86)	180.72 (143.68)	132.51 (120.15)	98.60 (110.67)	94.90 (94.07)	55.86 (60.92)
median	363.5	147	85.5	48	63	30
min-max	28-365	1-365	28-365	1-365	28-365	1-365
Good persistence (=365 days)n(%)	45 (48.19)	8513 (26.98)	45 (14.24)	404 (7.17)	8 (5.48)	23 (0.64)
Good persistence ( $\geq$ 183 days) n(%)	60 (62.65)	14258 (45.19)	85 (26.90)	1019 (18.09)	19 (13.01)	170 (4.74)
<b>Drug adherence within 1 year</b>						
PDC (% $\geq$ 0.80)	0.80	0.48	0.33	0.18	0.36	0.15

SD, standard deviation; n, number of patients with available data ; PDC, Proportion of Days Covered; PP1M, Paliperidone palmitate administered once a month; JMDC, Japan Medical Data Center; PKU, Peking University No.6 Hospital; XJH, Xijing hospital; SGA, second-generation antipsychotic

Supplementary Figure 2. Sensitivity analyses: Drug persistence, Kaplan-Meier curves.



JMDC, Japan Medical Data Center; PKU, Peking University No.6 Hospital; XJH, Xijing hospital; PP1M, Paliperidone palmitate administered once a month; SGA, second-generation antipsychotic

**Supplementary Table 3.** Sensitivity analysis, Cox proportional hazard models for persistence

Sensitivity analysis	JMDC(2012-2017)			PKU(2012-2017)			XJH(2012-2017)		
	Hazard ratio	95%CI	<i>P</i>	Hazard ratio	95%CI	<i>P</i>	Hazard ratio	95%CI	<i>P</i>
<b>60-day treatment gap</b>									
<b>Unadjusted</b>	0.83	0.73-0.94	<0.01	0.92	0.83-1.01	0.09	0.79	0.68-0.91	<0.01
<b>Adjusted</b>									
for age and sex	0.82	0.73-0.93	<0.01	0.88	0.79-0.97	<0.01	0.81	0.70-0.93	<0.01
for age, sex, baseline characteristics and index year	0.81	0.72-0.92	<0.01	0.94	0.85-1.05	0.27	0.83	0.71-0.97	0.02
<b>Index mono-treatment cohort</b>									
<b>Unadjusted</b>	0.69	0.57-0.85	<0.01	0.75	0.67-0.84	<0.01	0.60	0.51-0.71	<0.01
<b>Adjusted</b>									
for age and sex	0.69	0.57-0.85	<0.01	0.72	0.64-0.81	<0.01	0.61	0.52-0.73	<0.01
for age, sex, baseline characteristics and index year	0.64	0.52-0.52	<0.01	0.75	0.64-0.81	<0.01	0.61	0.51-0.73	<0.01

JMDC, Japan Medical Data Center; PKU, Peking University No.6 Hospital; XJH, Xijing hospital

**Supplementary Table 4. Sensitivity analysis, Logistic regression models for good adherence**

Sensitivity analysis	JMDC (2014-2017)			PKU (2012-2017)			XJH (2012-2017)		
	OR (sd)	95%CI	<i>P</i>	OR (sd)	95%CI	<i>P</i>	OR (sd)	95%CI	<i>P</i>
<b>Index mono-treatment cohort</b>									
<b>Unadjusted</b>	4.35(1.12)	2.63-7.20	<0.01	2.26 (0.28)	1.77-2.88	<0.01	3.19 (0.57)	2.25-4.53	<0.01
<b>Adjusted</b>									
for age and sex	4.38(1.13)	2.64-7.25	<0.01	2.37 (0.30)	1.85-3.04	<0.01	3.17 (0.57)	2.23-4.52	<0.01
for age and sex and baseline characteristics and index year	4.84(1.27)	2.90-8.08	<0.01	2.08 (0.28)	1.60-2.71	<0.01	2.46 (0.50)	1.66-3.66	<0.01

JMDC, Japan Medical Data Center; PKU, Peking University No.6 Hospital; XJH, Xijing hospital

OR: Odds ratio

\*60-day treatment gap does not affect good adherence.